cardiovascular disorders
Dilated Cardiomyopathy
Prognosis for Dilated Cardiomyopathy
 receptor blocker and neprilysin inhibitor [ARNI], mineralocorticoid receptor antagonists, sodium glucose cotransporter 2 protein (SGLT2) inhibitors, implantable cardioverter-defibrillators, or cardiac resynchronization therapy). About 20% of patients die in the first year and then about 10%/year thereafter; about 40 to 50% of deaths are sudden, due to a malignant arrhythmia ( Prognosis reference ). Prognosis is better for females than for males, and people of African ancestry survive about half as long as White people ( Prognosis is better if compensatory hypertrophy preserves ventricular wall thickness and is worse if ventricular walls thin markedly and the ventricle dilates. Patients whose dilated cardiomyopathy is well-compensated with treatment may be stable for many years. 1.Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy.Nat Rev Dis Primers2019;5(1):32. doi:10.1038/s41572-019-0084-1 2. 